These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 33777013

  • 1. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y, Wang J, Yang X, Yang J, Lu P, Zhao L, Li B, Pan H, Jiang Z, Shen X, Liang Z, Liang Y, Zhu H.
    Front Immunol; 2021; 12():628906. PubMed ID: 33777013
    [Abstract] [Full Text] [Related]

  • 2. Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma.
    Wang J, Wang Y, Pan H, Zhao L, Yang X, Liang Z, Shen X, Zhang J, Yang J, Zhu Y, Xun J, Liang Y, Lin Q, Liang H, Li M, Zhu H.
    Int J Mol Sci; 2023 Mar 12; 24(6):. PubMed ID: 36982500
    [Abstract] [Full Text] [Related]

  • 3. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
    Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM.
    Clin Cancer Res; 2011 Jul 15; 17(14):4719-30. PubMed ID: 21610146
    [Abstract] [Full Text] [Related]

  • 4. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
    Soltantoyeh T, Akbari B, Shahosseini Z, Mirzaei HR, Hadjati J.
    Front Immunol; 2024 Jul 15; 15():1362904. PubMed ID: 38855110
    [Abstract] [Full Text] [Related]

  • 5. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q, Wang H, Li H, Xu J, Tian K, Yang J, Lu Z, Zheng J.
    Oncotarget; 2017 Feb 07; 8(6):9488-9499. PubMed ID: 28055955
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
    Lee HH, Kim I, Kim UK, Choi SS, Kim TY, Lee D, Lee Y, Lee J, Jo J, Lee YT, Lee HJ, Kim SJ, Ahn JS.
    Neoplasia; 2022 Feb 07; 24(2):98-108. PubMed ID: 34954452
    [Abstract] [Full Text] [Related]

  • 7. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G, Zhang Q, Liu G, Li D, Zhang L, Gu Z, Tian H, Zhang Y, Tian X.
    Exp Cell Res; 2021 Dec 01; 409(1):112886. PubMed ID: 34673000
    [Abstract] [Full Text] [Related]

  • 8. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.
    Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE.
    J Immunother; 2010 Oct 01; 33(8):780-8. PubMed ID: 20842059
    [Abstract] [Full Text] [Related]

  • 9. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.
    Amit U, Uslu U, Verginadis II, Kim MM, Motlagh SAO, Diffenderfer ES, Assenmacher CA, Bicher S, Atoche SJ, Ben-Josef E, Young RM, June CH, Koumenis C.
    Proc Natl Acad Sci U S A; 2024 Jul 30; 121(31):e2403002121. PubMed ID: 39047033
    [Abstract] [Full Text] [Related]

  • 10. Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors.
    Wang G, Zhou X, Fucà G, Dukhovlinova E, Shou P, Li H, Johnston C, Mcguinness B, Dotti G, Du H.
    J Immunother Cancer; 2021 Apr 30; 9(4):. PubMed ID: 33795386
    [Abstract] [Full Text] [Related]

  • 11. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.
    Sci Transl Med; 2014 Nov 05; 6(261):261ra151. PubMed ID: 25378643
    [Abstract] [Full Text] [Related]

  • 12. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B, Liu M, Wang L, Liang B, Feng Y, Chen X, Shi Y, Zhang J, Ye X, Tian Y, Zhi C, Li J, Lian H, Wu Q, Zhang Z.
    Biochem Biophys Res Commun; 2020 Mar 26; 524(1):96-102. PubMed ID: 31980173
    [Abstract] [Full Text] [Related]

  • 13. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G, Zhang Q, Li D, Zhang L, Gu Z, Liu J, Liu G, Yang M, Gu J, Cui X, Pan Y, Tian X.
    Hum Immunol; 2021 Feb 26; 82(2):130-138. PubMed ID: 33341289
    [Abstract] [Full Text] [Related]

  • 14. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z, Jiang J, Wu X, Zhang M, Luo D, Zhang R, Li S, He Y, Bian H, Chen Z.
    Front Med; 2019 Feb 26; 13(1):57-68. PubMed ID: 30721445
    [Abstract] [Full Text] [Related]

  • 15. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
    Zhu Y, Wang K, Yue L, Zuo D, Sheng J, Lan S, Zhao Z, Dong S, Hu S, Chen X, Feng M.
    Pharmacol Res; 2024 May 26; 203():107186. PubMed ID: 38641176
    [Abstract] [Full Text] [Related]

  • 16. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell.
    Jafarzadeh L, Masoumi E, Alishah K, Mirzaei HR, Jamali A, Fallah-Mehrjardi K, Rostamian H, Khakpoor-Koosheh M, Meshkani R, Noorbakhsh F, Hadjati J.
    Iran J Allergy Asthma Immunol; 2020 Jun 23; 19(3):264-275. PubMed ID: 32615660
    [Abstract] [Full Text] [Related]

  • 17. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
    Chu GJ, Bailey CG, Nagarajah R, Liang O, Metierre C, Sagnella SM, Castelletti L, Yeo D, Adelstein S, Rasko JEJ.
    Cytotherapy; 2024 Apr 23; 26(4):325-333. PubMed ID: 38349311
    [Abstract] [Full Text] [Related]

  • 18. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
    Zhu Y, Zuo D, Wang K, Lan S, He H, Chen L, Chen X, Feng M.
    J Cancer Res Clin Oncol; 2023 Nov 23; 149(16):15027-15038. PubMed ID: 37612388
    [Abstract] [Full Text] [Related]

  • 19. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
    Li K, Xu J, Wang J, Lu C, Dai Y, Dai Q, Zhang W, Xu C, Wu S, Kang Y.
    Cancer Immunol Immunother; 2023 Apr 23; 72(4):917-928. PubMed ID: 36166071
    [Abstract] [Full Text] [Related]

  • 20. c-Met specific CAR-T cells as a targeted therapy for non-small cell lung cancer cell A549.
    Min J, Long C, Zhang L, Duan J, Fan H, Chu F, Li Z.
    Bioengineered; 2022 Apr 23; 13(4):9216-9232. PubMed ID: 35378051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.